News & Events

Learn about what's new with CMC Biologics

Catalyst Biosciences and CMC Biologics Announce Manufacturing Agreement for Catalyst's Next-Generation Factor VIIa Product CB 813d


Companies Committed to Establishing Manufacturing Capabilities for Next-Generation Factor Vlla CB 813d

Catalyst Plans to Initiate Clinical Pivotal Trial in Hemophilia A and B "Inhibitor" Patients in 2017

SOUTH SAN FRANCISCO, Calif. and BOTHELL, Wash. and COPENHAGEN, Denmark – May 24, 2016 (GLOBE NEWSWIRE) – Catalyst Biosciences, Inc. (NASDAQ:CBIO), a leading biotechnology company focused on discovering and developing novel protease therapeutics for treatments of serious medical conditions in the fields of hemostasis and anti-complement, and CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, today announced that they have entered into a manufacturing agreement for the process transfer and cGMP manufacturing of CB 813d, Catalyst’s next-generation long-acting Factor VIIa product. Catalyst is developing CB 813d for the treatment of hemophilia A and B inhibitor patients.

BIO International, June 6 - 9, Booth #5868


June 6 – 9, 2016 | BIO International, San Francisco, Calif.

Don’t miss BIO’s largest event! The BIO International Convention (BIO) attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. This event covers a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

Life Science Innovation Northwest, June 1 -2, Booth #216


June 1 – 2, 2016 Life Science Innovation Northwest, Seattle, Wash.

Join CMC Biologics at the 2016 Life Science Innovation Northwest (LSINW), North America’s Largest Fully-Integrated Life Science Exposition. June 1&2, 2016 @ the Washington State Convention Center in Seattle, WA.